PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
522.30%
G&A growth while TRVN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses change of 3069944.64% while TRVN maintains costs. Bruce Berkowitz would investigate efficiency.
230.56%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
230.56%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
243.75%
Interest expense growth above 1.5x TRVN's 1.56%. Michael Burry would check for over-leverage.
418.75%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
-202.01%
EBITDA decline while TRVN shows 16.83% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Operating income decline while TRVN shows 22.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Other expenses reduction while TRVN shows 210.72% growth. Joel Greenblatt would examine advantage.
-176.90%
Pre-tax income decline while TRVN shows 23.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Tax expense reduction while TRVN shows 43.49% growth. Joel Greenblatt would examine advantage.
-176.90%
Net income decline while TRVN shows 23.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS growth exceeding 1.5x TRVN's 23.62%. David Dodd would verify competitive advantages.
89.62%
Diluted EPS growth exceeding 1.5x TRVN's 23.62%. David Dodd would verify competitive advantages.
2567.99%
Share count change of 2567.99% while TRVN is stable. Bruce Berkowitz would verify approach.
2567.99%
Diluted share change of 2567.99% while TRVN is stable. Bruce Berkowitz would verify approach.